[Animal experimental studies on the therapeutic action of 5-(4-pyridino)-3-amino-1,2-dihydro-pyridinone (Cordemcura, AWD 08-250) in acute cardiocirculatory failure caused by poisoning by beta receptor blockers].
The therapeutical procedure in case of acute cardio-circulatory failure due to intoxication by beta-blockers has gained great importance owing to suicidal and accidental poisonings with lethal outcome. The use of beta-adrenergic agonists is difficult because a not predeterminable overdosage has to be applied in consequence of the competitive inhibition of the beta-receptor. Cardiotonics with a non-adrenergic mechanism of action thus make expect a surer handling. A severe cardio-circulatory failure is provoked by talinolol in the anaesthetized dog. The therapeutical effect of 4 mg/kg Cordemcura, given i.v. is represented by comparing the parameters cardiac rate, dp/dtmax, filling pressure in the left ventricle, arterial pressure, cardiac output, total peripheral resistance, and PQ time with a control group. The results prove a sure therapeutical effect, which is compared with other cardiotonics. A clinical use is recommended. The aptitude of the intoxication by beta-receptor blokkers as a model for the cardiac insufficiency is discussed.
Femmer
K
K
Heer
S
S
Poppe
H
H
D000319:Adrenergic beta-Antagonists / Q000506:poisoning*; D000631:Aminopyridines / Q000627:therapeutic use*; D000676:Amrinone; D000818:Animals; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D011412:Propanolamines / Q000506:poisoning
D000319:Adrenergic beta-Antagonists; D000631:Aminopyridines; D002316:Cardiotonic Agents; D011412:Propanolamines; C011550:talinolol; D000676:Amrinone
Tierexperimentelle Untersuchungen zur therapeutischen Wirkung von 5-(4-Pyridino)-3-amino-1,2-dihydro-pyridinon (Cordemcura, AWD 08-250) beim akuten Herz-Kreislauf-Versagen durch Intoxikation mit beta-Rezeptorenblocker.